You are here » Home » Companies » Company Overview » Earum Pharmaceuticals Ltd

Earum Pharmaceuticals Ltd.

BSE: 542724 Sector: Health care
NSE: N.A. ISIN Code: INE060601015
BSE 13:45 | 23 Sep 124.00 -2.70
(-2.13%)
OPEN

132.00

HIGH

132.00

LOW

124.00

NSE 05:30 | 01 Jan Earum Pharmaceuticals Ltd
OPEN 132.00
PREVIOUS CLOSE 126.70
VOLUME 2509
52-Week high 132.00
52-Week low 23.73
P/E 1771.43
Mkt Cap.(Rs cr) 153
Buy Price 124.00
Buy Qty 4600.00
Sell Price 125.00
Sell Qty 694.00
OPEN 132.00
CLOSE 126.70
VOLUME 2509
52-Week high 132.00
52-Week low 23.73
P/E 1771.43
Mkt Cap.(Rs cr) 153
Buy Price 124.00
Buy Qty 4600.00
Sell Price 125.00
Sell Qty 694.00

Earum Pharmaceuticals Ltd. (EARUMPHARMACEU) - Chairman Speech

Company chairman speech

Dear Shareholders

We have undertaken several strategic initiatives to drive improvement across operatingparameters and create a more efficient and sustainable business framework. Focusing ongrowth investments while rationalizing cost structures. Growth has been broad- basedacross key segments triggering the multiple demand drivers that underpin ourmulti-faceted business. The trend this year is once again looking positive.

The Technology driven solutions and re-engineering of its business and processes wouldhave stress on current year's performances to achieve long term sustainable marketpenetration and market share improvements.

Amid the pandemic and challenges thrown open by it the global pharmaceutical industryresponded with agility. Since March 2020 the industry has been hit with debilitatingrestrictions and impediments in reaching customers and supplying drugs to India and theworld. However the pharmaceutical industry has surpassed expectations in response to thisglobal crisis supplying drugs to over 150 countries besides meeting all domestic demands.

India's pharmaceutical industry has grown at a compounded growth rate of approximately11% in the domestic market and approximately 16% in exports over the past two decades.While the domestic market has grown at a similar pace to the gross domestic product (GDP)the overall growth has been driven by the industry's leadership in supplying genericformulations to markets across the globe.

According to IQVIA the global medicine market is expected to grow at 3-6% CAGR through2025 reaching about $1.6 trillion in total market size in 2025. This excludes spending onCOVID-19 vaccines where total cumulative spending through 2025 is projected to be $157Billion.

Emerging industry opportunities include innovation and R&D healthcare deliverymanufacturing and supply chain and market access. Efficient capacity building andoptimizing productivity will be essential in the next normal.

On behalf of the Board I would like to thank all our stakeholders includingshareholders investors bankers creditors and employees for their continued support. Iwould like to express my sincere gratitude to all the members of our Board for theircontinued insights and invaluable guidance as we explore new opportunities and move aheadwith confidence.

Warm regards

BHUMISHTH N. PATEL

CHAIRMAN & MANAGING DIRECTOR

.